Interesting data points in WSJ OpEd on Moderna vaccine hopeshttps://t.co/y9XJGZhxmX pic.twitter.com/qBPBlH1NIt
— M/I_Investments (@MI_Investments) May 19, 2020
Does anyone see an ethical conflict with releasing phase 1 clinical trial data when the sample size is 45 people and then after your stock rallies 20% that same day announcing a secondary after the close to the tune of $1.25 Billion? $MRNA pic.twitter.com/69qAhU956V
— JB (@JonathanByrne9) May 18, 2020
$MRNA Phase 1 only… Even the President and insider don't belive it because they are selling! pic.twitter.com/I0u1qVg5y0
— Michel Néboeuf (@MichelNeboeuf) May 18, 2020